COPE

Across TCGA pan-cancer cohorts, COPE mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated COPE data layer compared with 19 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher COPE mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated COPE expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where COPE mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	III,IV	0.421	0.916	.002	31	view →
HNSC	DFS	Tertile	III,IV	0.940	0.691	.004	21	view →
LUAD	OS	Tertile	II,III,IV	0.879	0.324	.014	6	view →
GBM	DFS	Quartile	All	0.231	0.483	.014	6	view →
CCRCC	DFS	Quartile	II,III,IV	0.887	0.198	.024	6	view →
PDAC	DFS	Tertile	All	0.892	0.782	.042	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

COPE–LSCC (DFS)

Open the LSCC breakdown →